Speaker Profile
M.D., Chief Executive Officer, BioAro
Biography
Dr. Anmol S. Kapoor is a cardiologist, entrepreneur, and founder of BioAro, a next-generation precision health company integrating genomics, multi-omics, and advanced AI to transform clinical care. Under his leadership, BioAro has built a global ecosystem spanning whole-genome and cancer sequencing, pharmacogenomics, microbiome testing, telomere biology, and longevity sciences.Driven to bridge the gaps of traditional medicine, Dr. Kapoor is advancing a prediction-, prevention-, and personalization-focused model that empowers clinicians across cardiology, oncology, dermatology, gastroenterology, gynecology, and longevity medicine.He also founded PanOmiQ, an AI-powered therapy-selection and multi-omics platform, and pioneered BioEMRBioELR, next-generation electronic record systems integrating AI into everyday practice. Through Kapoor Wealth Partners, he supports breakthrough ventures in medtech, biotech, digital health, and longevity.Internationally recognized in digital health and multi-omics innovation, Dr. Kapoor is shaping the global adoption of data-driven, patient-centered healthcare.
Talk
MultiOmics and AI: Pioneering the future of Longevity
MultiOmics and AI are redefining longevity science by uncovering hidden drivers of aging and enabling ultra-personalized prevention. This talk explores how integrated genomics, proteomics, microbiome insights, and AI-driven prediction models are transforming early detection, therapeutic targeting, and real-time health optimization shaping a new era of precision, preventive, and proactive longevity medicine.
Genomic Profiling Showcase:
BioAro Inc.
BioAro advances longevity through AI, LLM-powered BioIntelligence, and Axion hardware, integrating genomics, multi-omics lab testing, and real-time analysis. Its PanOmiQ platform unifies DNA, microbiome, and metabolic insights to deliver predictive, personalized, and proactive precision health.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Genomic Profiling Showcase will provide a 15-30 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.
